NYXH - Cantor picks RCEL as best 2024 medtech idea; bullish on PACB AXGN CERS
2024-01-21 16:50:33 ET
More on Pacific Biosciences of California, AVITA Medical, etc.
- AVITA Medical Positioned For Stellar 2024 With Skin Repair Innovation Momentum
- Pacific Biosciences' Revio And Onso Lead Looks Priced In For Now
- Reassessing Pacific Biosciences: Deep Dive Into Q3 2023 Revenue Surge And Market Dynamics
- Avita Medical misses Q4, FY23 prelim revenue estimate
- PacBio reports prelim Q4 revenue of $58.4M, shares fall
For further details see:
Cantor picks RCEL as best 2024 medtech idea; bullish on PACB, AXGN, CERS